SELLAS Life Sciences is rated Hold, with a $9.25 price target, as current valuation already reflects high REGAL trial success ...

Caris Life Sciences' Q2 featured accelerating clinical volumes, 68% gross margin, and strong early traction for Caris Detect.

Luma Group has closed its inaugural life sciences venture capital fund, LumaBio Fund I, with $410 million in committed ...

Dual recognition in 2026 Frost Radar™ reports marks a fourth consecutive year of Frost Radar leadership for LabVantage.

Precision medicine, clinical genomics, multi-omics and advanced therapies are driving demand for automation, bioinformatics and recurring reagents despite budget and talent constraints.Dublin, Sept.

Life sciences companies have long relied on evergreening strategies to strengthen patent exclusivity around innovative therapies.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

BioTech Social Inc. (BSI) has established an advisory board of experts from various fields to enhance financial ...

The convergence of artificial intelligence (AI) and life sciences is opening new possibilities in drug development, disease diagnosis, precision medicine and the modernization of traditional medicine, ...

Frazier Life Sciences has raised more than $1.1 billion in new commitments for its Public Fund through an oversubscribed ...